Skip to main content

Article Category

News

Article available in the folowing languages:

A COMPOSITION OBTAINED FROM A PIGMENT BELONGING TO THE FAMILY OF ANTHOCYANINS FOR THE TREATMENT OF TYPE 1 DIABETES DISEASE

The invention relates in particular to a composition, which is obtained from a pigment belonging to the family of anthocyanins and which features the ability to increase the insulin sensitivity and to trigger the insulin release.

Health

Technical Field The invention relates to a composition for the treatment of type 1 diabetes disease. The invention relates in particular to a composition, which is obtained from a pigment belonging to the family of anthocyanins and which features the ability to increase the insulin sensitivity and to trigger the insulin release. State of the Art Today, type 1 diabetes refers to the condition in which the insulin-producing beta cells in the pancreas become unable to function as a result of damage with autoimmune background. In this condition, the patient needs to employ the insulin injection throughout his/her lifetime. Currently, there is no treatment for this condition. There are attempts for local islet cell transplantation and direct igf-1 injection into the pancreas, but the results obtained are not stable. Regarding the state of the art, in the patent document no. WO05/097773 entitled “1,11-(1,2-ethynediyl)bis-benzene derivatives as ptp 1-b inhibitors”, the invention relates to the use in the application for carboxylic acid and insulin resistance or hyperglycemia, type I and/or type II, glucose tolerance irregularity, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, metabolic disorders associated with polycystic ovary syndrome (PCOS). On the other hand, the invention no. WO04/009544 entitled “2-cyano-4-fluoropyrrolidine derivative or salt thereof” relates to the formation of a composition with good effect for the inhibition of dipeptidyl peptidase IV and insulin-related diabetes (type I diabetes). Said invention relates in particular to a composition for obtaining the aforementioned effect in cases of non-insulin-dependent diabetes (type II diabetes), insulin resistant disorders and obesity. Further, the invention no. CA2343850 entitled “synergistic effect of a sulfonylurea and/or non-sulfonylurea K+ ATP Channel blocker, and a phosphodiesterase” relates to the method of application for the conditions of insulin-dependent diabetes, insulin resistance, syndrome X, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, polycystic ovary syndrome, cataract, hyperglycemia or glucose tolerance disorder. Consequently, the presence of the need for a composition for the treatment of type 1 diabetes disease and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant technical field. Object of the Invention In order to eliminate the disadvantages of the state of the art, it is an object of the invention to enable an increase in the insulin sensitivity and a triggering of the insulin release. Another object of the invention is to trigger the regeneration of the beta cells producing insulin in the pancreas. Another object of the invention is to provide a strong insulinotrophic (ability to trigger the insulin release) characteristic resulting from the ability to increase the beta-endorphine level. Another object of the invention is to provide that the insulin release triggered by acetylcholine is supported to the maximum extent, owing to ginsenoside rh2 contained in the composition. Still another object of the invention is to provide the ability to suppress the cytokines like tnf-alpha, which are detrimental to the beta cells. Still another object of the invention is to prevent the disruption of the repair process in the beta cells of the pancreas triggered by 28-hexahydroxy-olean-12-ene, 23-hexahydroxy-olean-12-ene and gymnemic acid IV. The structural and characteristic features and all the advantages of the invention will become more clearly understood from the detailed description provided below and therefore, the evaluation must also be made taking into consideration this detailed description. We hereby continue to detailed description of the invention in article part 2. Erdal Can Alkoclar & Metehan Yesil